Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics

Core Insights - Zai Lab Limited reported a revenue of $102.27 million for the quarter ended September 2024, marking a year-over-year increase of 47.7% and an EPS of -$0.42, an improvement from -$0.71 a year ago [1] - The revenue fell slightly short of the Zacks Consensus Estimate of $102.55 million, resulting in a surprise of -0.27%, while the EPS exceeded expectations by 44.00% compared to the consensus estimate of -$0.75 [1] Revenue Breakdown - Product Revenue for ZEJULA was $48.23 million, surpassing the three-analyst average estimate of $46.10 million [3] - Product Revenue for OPTUNE was $7.72 million, below the three-analyst average estimate of $9.52 million [3] - Product Revenue for VYVGART reached $27.27 million, exceeding the three-analyst average estimate of $26.50 million [3] - Product Revenue for NUZYRA was $10 million, falling short of the $12 million estimated by three analysts on average [3] - Product Revenue for QINLOCK was $8.64 million, surpassing the three-analyst average estimate of $7.54 million [3] Stock Performance - Shares of Zai Lab Limited have increased by 25.8% over the past month, significantly outperforming the Zacks S&P 500 composite, which saw a change of +3.3% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [4]